Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Breast Cancer Res
    October 2025
  1. MARCHENKO N, Nesbitt NM, Alexandrova E, Reisz JA, et al
    Biliverdin reductase B as a new target in breast cancer.
    Breast Cancer Res. 2025;27:179.
    >> Share

  2. LIEN HC, Li YC, Yun-Ju Huang R, Chen KC, et al
    Carcinomas exhibiting epithelial-mesenchymal transition manifest an M2 macrophage-enriched tumor immune microenvironment.
    Breast Cancer Res. 2025;27:177.
    >> Share

  3. CAO A, Fumagalli IA, Chen WY, Llanos AAM, et al
    Association between thoracic adiposity and survival in non-metastatic breast cancer.
    Breast Cancer Res. 2025;27:176.
    >> Share

  4. ZHANG R, Wang K, Wang S, Wang C, et al
    Multimodal deep learning model for prediction of breast cancer recurrence risk and correlation with oncotype DX.
    Breast Cancer Res. 2025;27:178.
    >> Share

  5. CHEN XY, Wang Y, Li DR, Liu BQ, et al
    Dietary index for gut microbiota, genetic risk, and incidence of breast cancer: a prospective study.
    Breast Cancer Res. 2025;27:175.
    >> Share

  6. SHEN J, Liu Y, Liu A, Gu X, et al
    Artificial intelligence-assisted ultrasound screening for breast cancer in China: a prospective, clustered, controlled, population-based study.
    Breast Cancer Res. 2025;27:173.
    >> Share

  7. MARTIN-BEJARANO P, Sanchez-Tapia EM, Jessica P, Martin-Gomez T, et al
    Functional characterization of BRCA1 variants of unknown significance using homologous recombination repair assays.
    Breast Cancer Res. 2025;27:174.
    >> Share

  8. AL DLALI M, Al Amri B, Al Zeheimi N, Al Busaidi R, et al
    Genomic landscape of cancer driver genes in Omani breast cancers: a pilot study.
    Breast Cancer Res. 2025;27:172.
    >> Share

    September 2025
  9. FONTANA A, Barbano R, Pasculli B, Mazza T, et al
    Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients.
    Breast Cancer Res. 2025;27:170.
    >> Share

  10. MAHMOUD MA, Winham SJ, Scott CG, Ehsan S, et al
    Interplay of BMI and volumetric breast density measures and breast cancer risk for black and white women.
    Breast Cancer Res. 2025;27:167.
    >> Share

  11. FANUCCI K, Yeh ED, Shi R, Qin L, et al
    Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
    Breast Cancer Res. 2025;27:171.
    >> Share

  12. KOYAMA Y, Muguruma M, Horimoto Y, Narui K, et al
    Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort study.
    Breast Cancer Res. 2025;27:169.
    >> Share

  13. VERMA D, Nandi D, Parida S, Saxena A, et al
    An enteropathogenic microbial toxin modulates the breast cancer epigenome resulting in concurrent silencing of tumor suppressor genes.
    Breast Cancer Res. 2025;27:163.
    >> Share

  14. SUNG H, Jiang C, Jatoi I, Jemal A, et al
    Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the United States.
    Breast Cancer Res. 2025;27:164.
    >> Share

  15. WONG C, Yang Q, Liang Y, Wei Z, et al
    AI-driven MRI biomarker for triple-class HER2 expression classification in breast cancer: a large-scale multicenter study.
    Breast Cancer Res. 2025;27:166.
    >> Share

  16. YANG Z, Lian X, Luo Y, Ye Q, et al
    Glutamine synthetase shields triple-negative breast cancer cells from ferroptosis in metastasis triggered by glutamine deprivation.
    Breast Cancer Res. 2025;27:165.
    >> Share

  17. OGONY JW, Pacheco-Spann LM, Arnold A, Cabezas JV, et al
    A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression.
    Breast Cancer Res. 2025;27:162.
    >> Share

  18. WANG M, Mo S, Li G, Zheng J, et al
    Deep learning and radiomics integration of photoacoustic/ultrasound imaging for non-invasive prediction of luminal and non-luminal breast cancer subtypes.
    Breast Cancer Res. 2025;27:161.
    >> Share

  19. KVIST A, Kampe A, Torngren T, Tesi B, et al
    Polygenic scores in Familial breast cancer cases with and without pathogenic variants and the risk of contralateral breast cancer.
    Breast Cancer Res. 2025;27:160.
    >> Share

  20. BOYACI C, Sun W, Hartman J, Acs B, et al
    Global scoring method of Ki67 immunohistochemistry in breast cancer demonstrates improved concordance using real-world multi-institutional data.
    Breast Cancer Res. 2025;27:159.
    >> Share

  21. WU HC, Liao Y, Lai Y, Lin PH, et al
    The plasma proteome and breast cancer risk.
    Breast Cancer Res. 2025;27:157.
    >> Share

  22. LI Y, Liu W, Yu Y, Wang Y, et al
    Early thelarche, reproductive hormones, and MRI-based breast density: a prospective study in China.
    Breast Cancer Res. 2025;27:158.
    >> Share

    August 2025
  23. TRINH L, Parks J, McDonald T, Roth A, et al
    Pre-diagnostic serum metabolome and breast cancer risk: a nested case-control study.
    Breast Cancer Res. 2025;27:156.
    >> Share

  24. ZHANG F, de Bock GH, Landman GW, Zhang Q, et al
    Longitudinal changes in metabolism-related metrics and breast cancer risk: a general population study.
    Breast Cancer Res. 2025;27:155.
    >> Share

  25. CHEN CH, Chen IC, Hsu CL, Lu TP, et al
    Characterization of the tumor immune microenvironment in pregnancy-associated breast cancer through multiplex immunohistochemistry and transcriptome analyses.
    Breast Cancer Res. 2025;27:154.
    >> Share

  26. WESTENEND PJ, Meurs C, Fernandez G, Prastawa M, et al
    External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.
    Breast Cancer Res. 2025;27:152.
    >> Share

  27. HAMILTON E, Pluard T, Wang JS, Morikawa A, et al
    Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res. 2025;27:151.
    >> Share

  28. KLAHR MP, Faheem K, Raghunathan RR, Wooster M, et al
    Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.
    Breast Cancer Res. 2025;27:150.
    >> Share

  29. PATEL R, Weil E, Bugamelli S, Carroll E, et al
    Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy.
    Breast Cancer Res. 2025;27:147.
    >> Share

  30. DANKNER M, Ouellet V, Lafon J, Ezzeddine R, et al
    Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomes.
    Breast Cancer Res. 2025;27:149.
    >> Share

  31. REEVES KW, Oulhote Y, Grandjean P, Nielsen F, et al
    Associations of perfluoroalkyl substances (PFAS) with terminal ductal lobular unit involution of the normal breast.
    Breast Cancer Res. 2025;27:148.
    >> Share

  32. RAVANI LV, Bagheri Z, Brufsky AM, Michellon I, et al
    Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:146.
    >> Share

  33. HUANG B, Zhang Y, Chen Z, Yuan Y, et al
    Exosome-delivered METTL14 drives hypoxia-induced proliferation, metastasis, and glycolysis of breast cancer cells through regulating TRIM16-mediated FGF7 ubiquitination.
    Breast Cancer Res. 2025;27:145.
    >> Share

  34. PARISSENTI AM, Pritzker LB, Dahle MA, Gythfeldt HVL, et al
    High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.
    Breast Cancer Res. 2025;27:143.
    >> Share

  35. SLEDGE GWJ, Xiu J, Solzak JP, Ribeiro J, et al
    Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis.
    Breast Cancer Res. 2025;27:144.
    >> Share

  36. HAYASHI K, Hoshii T, Ning M, Matsumoto M, et al
    Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K.
    Breast Cancer Res. 2025;27:142.
    >> Share

  37. LOPEZ-MIRANDA E, Perez-Garcia JM, Gion M, Ribelles N, et al
    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.
    Breast Cancer Res. 2025;27:141.
    >> Share

    July 2025
  38. LIU N, van der Velde JJS, Ramdjielal S, Koedoot E, et al
    Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC.
    Breast Cancer Res. 2025;27:140.
    >> Share

  39. ZAFAR S, Badshah Y, Shabbir M, Mussarat U, et al
    Missense variants in PRKCD: elucidating their potential association with breast cancer.
    Breast Cancer Res. 2025;27:139.
    >> Share

  40. HERNANDEZ A, Puppala A, Hedlich-Dwyer J, Mukherjee N, et al
    Short-term consumption of the modified standard American diet perturbed the metabolic balance and altered DNA damage in MMTV-PyMT transgenic mice.
    Breast Cancer Res. 2025;27:138.
    >> Share

  41. LEE CH, Park SY, Lee JS, Kim DS, et al
    MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer.
    Breast Cancer Res. 2025;27:136.
    >> Share

  42. BOETTCHER L, Greimeier S, Borgmann K, Mughal SS, et al
    Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer.
    Breast Cancer Res. 2025;27:137.
    >> Share

  43. DUAN F, Hua X, Lu W, Gui X, et al
    Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.
    Breast Cancer Res. 2025;27:135.
    >> Share

  44. WHI W, Shin J, Kim JY, Ahn HK, et al
    Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.
    Breast Cancer Res. 2025;27:134.
    >> Share

  45. TUOKKOLA JE, Reese LE, Wang Y, O'Connor CH, et al
    Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.
    Breast Cancer Res. 2025;27:132.
    >> Share

  46. DO TTN, Block I, Burton M, Sorensen KP, et al
    Multi-transcriptomics predicts clinical outcome in systemically untreated breast cancer patients with extensive follow-up.
    Breast Cancer Res. 2025;27:133.
    >> Share

  47. SKOURTI E, Seip K, Mensali N, Jabeen S, et al
    Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.
    Breast Cancer Res. 2025;27:131.
    >> Share

  48. JONG CL, Siesling S, Puts GCWM, Jager A, et al
    The impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study.
    Breast Cancer Res. 2025;27:129.
    >> Share

  49. HOLM JB, Skovbjerg SB, Nielsen HM, Christiansen P, et al
    The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer.
    Breast Cancer Res. 2025;27:130.
    >> Share

  50. LUO Q, Zhang L, Hao Y, Xu C, et al
    Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4.
    Breast Cancer Res. 2025;27:128.
    >> Share

  51. RIZVI N, Mucaki EJ, Salmini EL, Zhang M, et al
    Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.
    Breast Cancer Res. 2025;27:127.
    >> Share

  52. DENNAOUI R, Radler PD, Wicker MN, Vistisen K, et al
    Overexpression of TSG101 causes the development of adenosquamous mammary carcinoma.
    Breast Cancer Res. 2025;27:126.
    >> Share

  53. XIONG G, He D, Napier D, Chen J, et al
    Hsp47 drives obesity-associated breast cancer progression by enhancing asporin deposition in adipose tissue.
    Breast Cancer Res. 2025;27:125.
    >> Share

  54. ZENG Y, Xu Z, Huang J, Yi Q, et al
    THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer.
    Breast Cancer Res. 2025;27:124.
    >> Share

  55. HAMILTON EP, Patel MR, Borges VF, Meisel JL, et al
    Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
    Breast Cancer Res. 2025;27:119.
    >> Share

  56. MULDER CV, Jongbloed EM, Liefaard MC, Makrodimitris S, et al
    A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer.
    Breast Cancer Res. 2025;27:120.
    >> Share

  57. HUANG Z, Mo S, Li G, Tian H, et al
    Prognosticating axillary lymph node metastasis in breast cancer through integrated photoacoustic imaging, ultrasound, and clinical parameters.
    Breast Cancer Res. 2025;27:123.
    >> Share

  58. POURALI G, Liu M, Sherpa SS, Hardi A, et al
    Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials.
    Breast Cancer Res. 2025;27:118.
    >> Share

  59. BULLOCK E, Rozyczko A, Shabbir S, Tsoupi I, et al
    Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma.
    Breast Cancer Res. 2025;27:121.
    >> Share

  60. HIS M, Baggio I, Chabaud S, Tassy L, et al
    Long-term weight change among breast cancer patients treated with chemotherapy: a longitudinal study over 13 years.
    Breast Cancer Res. 2025;27:117.
    >> Share

  61. CHAKI M, Benrashid M, Puri S, Sivakumar S, et al
    Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.
    Breast Cancer Res. 2025;27:122.
    >> Share

    June 2025
  62. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2025;27:116.
    >> Share

  63. LEON-FERRE RA, Dimitroff K, Yau C, Giridhar KV, et al
    Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Breast Cancer Res. 2025;27:115.
    >> Share

  64. RYU S, Kim HS, Lee S, Yoon SH, et al
    Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models.
    Breast Cancer Res. 2025;27:113.
    >> Share

  65. CORRADO A, Lorito N, Anemone A, Carella A, et al
    In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer.
    Breast Cancer Res. 2025;27:112.
    >> Share

  66. CAIRAT M, Olesen M, Olivier E, Pottegard A, et al
    Systemic glucocorticoids and the risk of breast cancer in a large nationwide case-control study.
    Breast Cancer Res. 2025;27:114.
    >> Share

  67. CHANG AC, Balic M, Bartholow T, Bhargava R, et al
    Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer.
    Breast Cancer Res. 2025;27:111.
    >> Share

  68. CHAO X, Wu Y, Cai X, He J, et al
    Exploratory multi-cohort, multi-reader study on the clinical utility of a deep learning model for transforming cryosectioned to formalin-fixed, paraffin-embedded (FFPE) images in breast lesion diagnosis.
    Breast Cancer Res. 2025;27:110.
    >> Share

  69. IESATO A, Suzuka J, Otsuji K, Osako T, et al
    Axillary adipose tissue-derived lymphatic endothelial cells exhibit distinct transcriptomic signatures reflecting lymphatic invasion status in breast cancer.
    Breast Cancer Res. 2025;27:109.
    >> Share

  70. WILHELM A, Flynn C, Hammer E, Roessler J, et al
    Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.
    Breast Cancer Res. 2025;27:107.
    >> Share

  71. GAO L, Zhang L, Liu J, Wang L, et al
    Discovery and validation of cell-free DNA methylation markers for specific diagnosis, differentiation from benign tumors, and prognosis of breast cancer.
    Breast Cancer Res. 2025;27:108.
    >> Share

  72. VAN BAELEN K, Nguyen HL, Richard F, Zels G, et al
    Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
    Breast Cancer Res. 2025;27:106.
    >> Share

  73. ZHONG X, Deng J, Lu P, Zuo Z, et al
    Wearable device for axillary lymph node screening in breast cancer based on infrared thermography and artificial intelligence.
    Breast Cancer Res. 2025;27:104.
    >> Share

  74. ODZER N, Chehayeb RJ, Schellhorn SE, Lustberg M, et al
    Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States.
    Breast Cancer Res. 2025;27:102.
    >> Share

  75. DENNIS SR, Tsukioki T, Cottone G, Zhou W, et al
    DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls.
    Breast Cancer Res. 2025;27:103.
    >> Share

  76. DING P, Pei S, Zhai Y, Qu Z, et al
    Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing.
    Breast Cancer Res. 2025;27:101.
    >> Share

  77. CHEN C, Yao H, Jie H, Liang Z, et al
    SENP5 drives breast cancer progression through deSUMOYlation of CDK1.
    Breast Cancer Res. 2025;27:100.
    >> Share

  78. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Correction: Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2025;27:99.
    >> Share

  79. HU C, Zhang S, Duan F, Huang X, et al
    Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis.
    Breast Cancer Res. 2025;27:96.
    >> Share

  80. ZHONG HJ, Zhen Y, Chen S, Shi W, et al
    Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care.
    Breast Cancer Res. 2025;27:97.
    >> Share

    May 2025
  81. LIU PH, Tsai CF, Hsu YC, Wu CY, et al
    Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study.
    Breast Cancer Res. 2025;27:95.
    >> Share

  82. ROY R, Schunkert EM, Olivova P, Gilar M, et al
    Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.
    Breast Cancer Res. 2025;27:94.
    >> Share

  83. XUAN W, Li W, Ke L, Shen Y, et al
    Investigating the mechanism of inositol against paclitaxel chemoresistance on triple-negative breast cancer by using 7T multiparametric MRI and mitochondrial changes.
    Breast Cancer Res. 2025;27:93.
    >> Share

  84. GAO Y, Zuo L, Zheng Y, Sun K, et al
    NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Breast Cancer Res. 2025;27:92.
    >> Share

  85. SPYCHALSKI GB, Lin AA, Yang SJ, Shen H, et al
    miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer.
    Breast Cancer Res. 2025;27:90.
    >> Share

  86. MUNHOZ J, Newell M, Goruk S, Ghosh S, et al
    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial.
    Breast Cancer Res. 2025;27:91.
    >> Share

  87. KIM H, Chun JW, Hwang J, Yun SG, et al
    Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study.
    Breast Cancer Res. 2025;27:89.
    >> Share

  88. MAVADDAT N, Frost D, Zhao E, Barnes DR, et al
    Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE.
    Breast Cancer Res. 2025;27:87.
    >> Share

  89. CHEUNG AM, Wang D, Quintayo MA, Yerofeyeva Y, et al
    Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping.
    Breast Cancer Res. 2025;27:88.
    >> Share

  90. HUANG Y, Cao Y, Chen H, Lan X, et al
    Quantifying tumor morphological complexity based on pretreatment MRI fractal analysis for predicting pathologic complete response and survival in breast cancer: a retrospective, multicenter study.
    Breast Cancer Res. 2025;27:86.
    >> Share

  91. JEONG J, Yoo K, Lee J, Shin JH, et al
    Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer.
    Breast Cancer Res. 2025;27:85.
    >> Share

  92. KIM JS, Lee JH, Yeon Y, An D, et al
    Correction: Predicting Nottingham grade in breast cancer digital pathology using a foundation model.
    Breast Cancer Res. 2025;27:84.
    >> Share

  93. MOSHINA N, Gjesvik J, Hovda T, Koch HW, et al
    Mammographic density by time and breast: a retrospective cohort study from BreastScreen Norway.
    Breast Cancer Res. 2025;27:83.
    >> Share

  94. DIAZ-SANTANA MV, Park J, Rogers M, O'Brien KM, et al
    Depression, antidepressant use, and breast cancer incidence in the Sister Study cohort.
    Breast Cancer Res. 2025;27:82.
    >> Share

  95. CARLSON EG, Lopez JC, Yamaguchi Y, Gibson J, et al
    CD105(+) fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiation.
    Breast Cancer Res. 2025;27:81.
    >> Share

  96. VENETIS K, Cursano G, Scafetta R, Giachetti PPMB, et al
    ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.
    Breast Cancer Res. 2025;27:79.
    >> Share

  97. XU Z, Zhong S, Gao Y, Huo J, et al
    Optimizing breast lesions diagnosis and decision-making with a deep learning fusion model integrating ultrasound and mammography: a dual-center retrospective study.
    Breast Cancer Res. 2025;27:80.
    >> Share

  98. ULANDAY KT, Topaz M, Shekelle J, Gibbons M, et al
    Cancers missed, women dismissed yet persist: natural language processing of online forums.
    Breast Cancer Res. 2025;27:78.
    >> Share

  99. ROBINSON TJ, Liveringhouse CL, Wilson C, Friedman S, et al
    Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets.
    Breast Cancer Res. 2025;27:77.
    >> Share

  100. WU SY, Sharma S, Wu K, Tyagi A, et al
    Retraction Note: Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
    Breast Cancer Res. 2025;27:75.
    >> Share

  101. MA X, Zhang B, Yin X, Yang S, et al
    CPT1A/HIF-1alpha positive feedback loop induced fatty acid oxidation metabolic pathway contributes to the L-ascorbic acid-driven angiogenesis in breast cancer.
    Breast Cancer Res. 2025;27:74.
    >> Share

  102. HEUMANN P, Benner A, Behrens S, Chang-Claude J, et al
    Prognostic value of cancer-related fatigue at the end of radiotherapy for overall survival >/= 10 years in women with breast cancer.
    Breast Cancer Res. 2025;27:76.
    >> Share

  103. VETHENCOURT A, Trinidad EM, Dorca E, Petit A, et al
    Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.
    Breast Cancer Res. 2025;27:68.
    >> Share

  104. MANGIOLA S, Brown R, Zhan C, Berthelet J, et al
    Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.
    Breast Cancer Res. 2025;27:73.
    >> Share

  105. WANG X, Huang Y, Shi J, Cao Y, et al
    Biomechanical parameters quantified by MR elastography for predicting response to neoadjuvant chemotherapy and disease-free survival in breast cancer: a prospective longitudinal study.
    Breast Cancer Res. 2025;27:72.
    >> Share

  106. PHI LTH, Cheng Y, Funakoshi Y, Bertucci F, et al
    AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.
    Breast Cancer Res. 2025;27:70.
    >> Share

  107. WANG B, Chen X, Li H, Sun J, et al
    8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.
    Breast Cancer Res. 2025;27:71.
    >> Share

  108. HEYDARI S, Tajik F, Safaei S, Kamani F, et al
    The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review.
    Breast Cancer Res. 2025;27:69.
    >> Share

  109. BRANTLEY KD, Jones ME, Tamimi RM, Rosner BA, et al
    Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts.
    Breast Cancer Res. 2025;27:67.
    >> Share

  110. KIM SC, Kim GH, Park JH, Lee KH, et al
    Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.
    Breast Cancer Res. 2025;27:66.
    >> Share

  111. DENG N, Kang W, Du J, Rong X, et al
    Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein.
    Breast Cancer Res. 2025;27:63.
    >> Share

  112. COMINO-MENDEZ I, Velasco-Suelto J, Pascual J, Lopez-Lopez E, et al
    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer.
    Breast Cancer Res. 2025;27:65.
    >> Share

  113. DONG M, Chen J, Lu N, Wang S, et al
    Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis.
    Breast Cancer Res. 2025;27:64.
    >> Share

    April 2025
  114. KONG L, Hu S, Zhao Y, Huang Y, et al
    Neutrophil extracellular traps induced by neoadjuvant chemotherapy of breast cancer promotes vascular endothelial damage.
    Breast Cancer Res. 2025;27:61.
    >> Share

  115. LI X, Lin Z, Qiu C, Zhang Y, et al
    Transfer learning drives automatic HER2 scoring on HE-stained WSIs for breast cancer: a multi-cohort study.
    Breast Cancer Res. 2025;27:62.
    >> Share

  116. MESA-EGUIAGARAY I, Wild SH, Williams LJ, Jin K, et al
    Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland.
    Breast Cancer Res. 2025;27:59.
    >> Share

  117. DAI J, Rozenblit M, Li X, Shan NL, et al
    Genomic alterations in normal breast tissues preceding breast cancer diagnosis.
    Breast Cancer Res. 2025;27:60.
    >> Share

  118. KIM JS, Lee JH, Yeon Y, An DY, et al
    Predicting Nottingham grade in breast cancer digital pathology using a foundation model.
    Breast Cancer Res. 2025;27:58.
    >> Share

  119. DU J, Shi J, Sun D, Wang Y, et al
    Machine learning prediction of HER2-low expression in breast cancers based on hematoxylin-eosin-stained slides.
    Breast Cancer Res. 2025;27:57.
    >> Share

  120. ZHAO Y, Song Y, Li X, Guo A, et al
    Retraction Note: Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.
    Breast Cancer Res. 2025;27:56.
    >> Share

  121. SCHOEMAKER MJ, Ellington T, Nichols HB, Wright LB, et al
    Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women.
    Breast Cancer Res. 2025;27:55.
    >> Share

  122. HAN J, Zhai X, Tao X, Li Y, et al
    Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.
    Breast Cancer Res. 2025;27:54.
    >> Share

  123. YAGHJYAN L, Heng YJ, Sardella BR, Murthy D, et al
    Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue.
    Breast Cancer Res. 2025;27:53.
    >> Share

  124. DU S, Xie W, Gao S, Zhao R, et al
    Early prediction of neoadjuvant therapy response in breast cancer using MRI-based neural networks: data from the ACRIN 6698 trial and a prospective Chinese cohort.
    Breast Cancer Res. 2025;27:52.
    >> Share

  125. WANG Y, Jiang Y, Ding F, Lu J, et al
    Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy.
    Breast Cancer Res. 2025;27:51.
    >> Share

  126. KAISER E, Weber R, Hirschstein M, Mazid H, et al
    Dynamics of T cell subpopulations and plasma cytokines during the first year of antineoplastic therapy in patients with breast cancer: the BEGYN-1 study.
    Breast Cancer Res. 2025;27:50.
    >> Share

    March 2025
  127. WANG F, Li W, Han G, Xie J, et al
    A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.
    Breast Cancer Res. 2025;27:47.
    >> Share

  128. YUAN X, Rosen JM
    Histone acetylation modulators in breast cancer.
    Breast Cancer Res. 2025;27:49.
    >> Share

  129. LIPERT BA, Siemens KN, Khan A, Airey R, et al
    CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance.
    Breast Cancer Res. 2025;27:48.
    >> Share

  130. WU X, Li Y, Chen J, Chen J, et al
    Multimodal recurrence risk prediction model for HR+/HER2- early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features.
    Breast Cancer Res. 2025;27:27.
    >> Share

  131. KRESOVICH JK, Reid BM, O'Brien KM, Xu Z, et al
    DNA methylation-predicted plasma protein levels and breast cancer risk.
    Breast Cancer Res. 2025;27:46.
    >> Share

  132. LV H, Yue J, Zhang Q, Xu F, et al
    Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China.
    Breast Cancer Res. 2025;27:45.
    >> Share

  133. FORTUNATO A, Mallo D, Cisneros L, King LM, et al
    Evolutionary measures show that recurrence of DCIS is distinct from progression to breast cancer.
    Breast Cancer Res. 2025;27:43.
    >> Share

  134. BERGHOLTZ H, Norum JH, Lien TG, Skrede ML, et al
    B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.
    Breast Cancer Res. 2025;27:44.
    >> Share

  135. BAEK SH, Lee MJ, Kook Y, Bae SJ, et al
    Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer.
    Breast Cancer Res. 2025;27:42.
    >> Share

  136. LI M, Zhou S, Lv H, Cai M, et al
    Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations.
    Breast Cancer Res. 2025;27:41.
    >> Share

  137. INGLE JN, Suman VJ, Solanki MH, Passow MR, et al
    Evaluation of the androgen receptor in patients with ERalpha-positive early breast cancer treated with adjuvant tamoxifen +/- fluoxymesterone.
    Breast Cancer Res. 2025;27:40.
    >> Share

  138. DE MORAES FCA, de Castro Ribeiro CHD, Pessoa FDDL, Chaves JR, et al
    Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.
    Breast Cancer Res. 2025;27:39.
    >> Share

  139. ZHANG D, Jahanfar S, Rabinowitz JB, Dower J, et al
    Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2025;27:38.
    >> Share

  140. HECKENBACH I, Peila R, Benz C, Weinmann S, et al
    Cellular senescence predicts breast cancer risk from benign breast disease biopsy images.
    Breast Cancer Res. 2025;27:37.
    >> Share

  141. DENT R, Cortes J, Park YH, Munoz-Couselo E, et al
    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.
    Breast Cancer Res. 2025;27:35.
    >> Share

  142. VIART NM, Renault AL, Eon-Marchais S, Jiao Y, et al
    Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile.
    Breast Cancer Res. 2025;27:36.
    >> Share

  143. LEE J, Ham S, Kim N, Park HS, et al
    Development of a deep learning-based model for guiding a dissection during robotic breast surgery.
    Breast Cancer Res. 2025;27:34.
    >> Share

  144. WARD AV, Riley D, Cosper KE, Finlay-Schultz J, et al
    Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells.
    Breast Cancer Res. 2025;27:32.
    >> Share

  145. USUI T, Miyake T, Watabe T, Kato H, et al
    Preclinical evaluation of (64)Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.
    Breast Cancer Res. 2025;27:33.
    >> Share

  146. WU S, Jiang B, Li Z, Tang Y, et al
    Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing.
    Breast Cancer Res. 2025;27:31.
    >> Share

    February 2025
  147. FENG X, Shi Y, Wu M, Cui G, et al
    Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model.
    Breast Cancer Res. 2025;27:30.
    >> Share

  148. SHI Q, Yang W, Ouyang Y, Liu Y, et al
    Correction: CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
    Breast Cancer Res. 2025;27:28.
    >> Share

  149. WU X, Xia Y, Lou X, Huang K, et al
    Decoding breast cancer imaging trends: the role of AI and radiomics through bibliometric insights.
    Breast Cancer Res. 2025;27:29.
    >> Share

  150. MARKS JR, Zhang D, Hardman T, Chen YY, et al
    Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).
    Breast Cancer Res. 2025;27:26.
    >> Share

  151. DUIVON M, Christy F, Thomas E, Lequesne J, et al
    Interaction between APOE E4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.
    Breast Cancer Res. 2025;27:25.
    >> Share

  152. SABETI S, Larson NB, Boughey JC, Stan DL, et al
    Ultrasound-based quantitative microvasculature imaging for early prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
    Breast Cancer Res. 2025;27:24.
    >> Share

  153. HUNTER NB, Peterson LM, Specht JM, Mankoff DA, et al
    Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:23.
    >> Share

  154. SCHMIDT G, Gluz O, Christgen M, Reinisch M, et al
    HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
    Breast Cancer Res. 2025;27:22.
    >> Share

  155. ZHANG L, Liu Y, Yang C, Ma J, et al
    Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study.
    Breast Cancer Res. 2025;27:21.
    >> Share

  156. YANG JS, Cao JM, Sun R, Zhou XJ, et al
    SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression.
    Breast Cancer Res. 2025;27:20.
    >> Share

  157. LOPEZ M, Spehner L, Andre F, Viot J, et al
    Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.
    Breast Cancer Res. 2025;27:19.
    >> Share

  158. WHITMARSH T, Cope W, Carmona-Bozo J, Manavaki R, et al
    Quantifying the tumour vasculature environment from CD-31 immunohistochemistry images of breast cancer using deep learning based semantic segmentation.
    Breast Cancer Res. 2025;27:17.
    >> Share

  159. GETZ KR, Jeon MS, Liu L, Liu L, et al
    Metabolites and lipid species mediate the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women.
    Breast Cancer Res. 2025;27:18.
    >> Share

  160. HENRICKS J, Haddad T, Ahmed O, Schoenhals J, et al
    Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer.
    Breast Cancer Res. 2025;27:16.
    >> Share

    January 2025
  161. SHI Q, Yang W, Ouyang Y, Liu Y, et al
    CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
    Breast Cancer Res. 2025;27:15.
    >> Share

  162. HABERLE L, Erber R, Gass P, Hein A, et al
    Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers.
    Breast Cancer Res. 2025;27:13.
    >> Share

  163. EHLERS FAI, Blise KE, Betts CB, Sivagnanam S, et al
    Natural killer cells occupy unique spatial neighborhoods in HER2(-) and HER2(+) human breast cancers.
    Breast Cancer Res. 2025;27:14.
    >> Share

  164. DEMICHELE A, Dueck AC, Hlauschek D, Martin M, et al
    Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
    Breast Cancer Res. 2025;27:12.
    >> Share

  165. GABER M, Quentel A, Holmes J, Lepetit C, et al
    Obesity increases DNA damage in the breast epithelium.
    Breast Cancer Res. 2025;27:11.
    >> Share

  166. ZAREAN E, Li S, Wong EM, Makalic E, et al
    Tumour DNA methylation markers associated with breast cancer survival: a replication study.
    Breast Cancer Res. 2025;27:9.
    >> Share

  167. YOUNG KS, Hancock GR, Fink EC, Zigrossi A, et al
    Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells.
    Breast Cancer Res. 2025;27:10.
    >> Share

  168. PACAUD R, Thomas S, Chaudhuri S, Lazar A, et al
    Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.
    Breast Cancer Res. 2025;27:8.
    >> Share

  169. AGUILAR D, Garza-Rodriguez ML, Muniz-Garza CE, Nunez FA, et al
    Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.
    Breast Cancer Res. 2025;27:7.
    >> Share

  170. HU K, Wu Y, Huang Y, Zhou M, et al
    Annotation-free deep learning algorithm trained on hematoxylin & eosin images predicts epithelial-to-mesenchymal transition phenotype and endocrine response in estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2025;27:6.
    >> Share

  171. KIM SS, Park I, Kim J, Ka NL, et al
    Secreted LGALS3BP facilitates distant metastasis of breast cancer.
    Breast Cancer Res. 2025;27:4.
    >> Share

  172. MOSTOFSKY E, Buring JE, Come SE, Tung NM, et al
    Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study.
    Breast Cancer Res. 2025;27:5.
    >> Share

  173. PARK J, Chang ES, Kim JY, Chelakkot C, et al
    Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:3.
    >> Share

  174. FANG Z, Ren G, Ke S, Xu Q, et al
    Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study.
    Breast Cancer Res. 2025;27:2.
    >> Share

  175. MAJUMDER S, Mishra S, Shinde N, Cuitino MC, et al
    Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models.
    Breast Cancer Res. 2025;27:1.
    >> Share

    December 2024
  176. PRZANOWSKA RK, Labban N, Przanowski P, Hawes RB, et al
    Patient-derived response estimates from zero-passage organoids of luminal breast cancer.
    Breast Cancer Res. 2024;26:192.
    >> Share

  177. WANG WK, Lin HY, Lin CH, Lee HH, et al
    GRK6 palmitoylation dictates triple-negative breast cancer metastasis via recruiting the beta-Arrestin 2/MAPKs/NF-kappaB signaling axis.
    Breast Cancer Res. 2024;26:193.
    >> Share

  178. LIAO CC, Long Y, Tsai ML, Lin CY, et al
    G-cleave LC3B biosensor: monitoring autophagy and assessing resveratrol's synergistic impact on doxorubicin-induced apoptosis in breast cancer cells.
    Breast Cancer Res. 2024;26:190.
    >> Share

  179. LESLIE SALEWON M, Pathak R, Dooley WC, Squires RA, et al
    Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare.
    Breast Cancer Res. 2024;26:191.
    >> Share

  180. YIANGOU K, Mavaddat N, Dennis J, Zanti M, et al
    Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.
    Breast Cancer Res. 2024;26:189.
    >> Share

  181. CHOI HL, Jeong SM, Jeon KH, Kim B, et al
    Depression risk among breast cancer survivors: a nationwide cohort study in South Korea.
    Breast Cancer Res. 2024;26:188.
    >> Share

  182. GIRNIUS N, Henstridge AZ, Marks B, Yu JK, et al
    Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.
    Breast Cancer Res. 2024;26:187.
    >> Share

  183. CARUSO JA, Chen-Tanyolac C, Tlsty TD
    A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state.
    Breast Cancer Res. 2024;26:184.
    >> Share

  184. PUPPO M, Croset M, Ceresa D, Valluru MK, et al
    Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis.
    Breast Cancer Res. 2024;26:186.
    >> Share

  185. KOHLER KT, Kim J, Villadsen R, Ronnov-Jessen L, et al
    Oncogene activated human breast luminal progenitors contribute basally located myoepithelial cells.
    Breast Cancer Res. 2024;26:183.
    >> Share

  186. BAE SJ, Kim JH, Kim MJ, Kook Y, et al
    Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study.
    Breast Cancer Res. 2024;26:182.
    >> Share

  187. MITSIADES IR, Onozato M, Iafrate AJ, Hicks D, et al
    ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.
    Breast Cancer Res. 2024;26:185.
    >> Share

  188. GAO SY, Lin TC, Liu LC, Chen WL, et al
    Intraoperative radiotherapy versus whole breast radiotherapy in early-stage breast cancer: a retrospective outcome analysis based on ASTRO guidelines on PBI.
    Breast Cancer Res. 2024;26:181.
    >> Share

  189. HAN E, Choi HY, Kwon HJ, Chung YR, et al
    Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:180.
    >> Share

  190. TERRY MB, English DR, Freudenheim JL, Lauby-Secretan B, et al
    Alcohol cessation and breast cancer risk stratified by hormone receptor status.
    Breast Cancer Res. 2024;26:179.
    >> Share

  191. LEE DN, Li Y, Olsson LT, Hamilton AM, et al
    Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers.
    Breast Cancer Res. 2024;26:177.
    >> Share

  192. DEBELJAK M, Cho S, Downs BM, Considine M, et al
    Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.
    Breast Cancer Res. 2024;26:178.
    >> Share

  193. COUNCELL KA, Polcari AM, Nordgren R, Skolarus TA, et al
    Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study.
    Breast Cancer Res. 2024;26:176.
    >> Share

  194. DE LA CRUZ P, McAdams J, Morales Aquino M, Fernandez AI, et al
    NF-kappaB associated markers of prognosis in early and metastatic triple negative breast cancer.
    Breast Cancer Res. 2024;26:175.
    >> Share

    November 2024
  195. JUNG J, Kim NH, Park J, Lim D, et al
    Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer.
    Breast Cancer Res. 2024;26:174.
    >> Share

  196. LIU J, Sun W, Li N, Li H, et al
    Uncovering immune cell-associated genes in breast cancer: based on summary data-based Mendelian randomized analysis and colocalization study.
    Breast Cancer Res. 2024;26:172.
    >> Share

  197. MORGAN E, O'Neill C, Shah R, Langselius O, et al
    Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2024;26:171.
    >> Share

  198. SHAHROUZI P, Azimzade Y, Brankiewicz-Kopcinska W, Bhatia S, et al
    Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response.
    Breast Cancer Res. 2024;26:170.
    >> Share

  199. GORANSSON S, Hernandez-Varas P, Hammarstrom M, Hellgren R, et al
    Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.
    Breast Cancer Res. 2024;26:163.
    >> Share

  200. CHERNOSKY NM, Tamagno I, Polak KL, Chan ER, et al
    Toll-Like receptor 3-mediated interferon-beta production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.
    Breast Cancer Res. 2024;26:167.
    >> Share

  201. TEHRANIFAR P, Lee Argov EJ, Athilat S, Liao Y, et al
    Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case-control study.
    Breast Cancer Res. 2024;26:166.
    >> Share

  202. KRESOVICH JK, Guranich C, Houghton S, Qian J, et al
    Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.
    Breast Cancer Res. 2024;26:169.
    >> Share

  203. FOO J, Gentile F, Massah S, Morin H, et al
    Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2).
    Breast Cancer Res. 2024;26:168.
    >> Share

  204. KOOK Y, Lee YJ, Chu C, Jang JS, et al
    Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.
    Breast Cancer Res. 2024;26:164.
    >> Share

  205. GEHLING GM, Alfaqih M, Pruinelli L, Starkweather A, et al
    A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.
    Breast Cancer Res. 2024;26:165.
    >> Share

  206. BI K, Chen M, Zhao Q, Yang T, et al
    The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER + breast cancer but not ER- breast cancer.
    Breast Cancer Res. 2024;26:161.
    >> Share

  207. YOHANNES M, Desalegn Z, Bauer M, Stuckrath K, et al
    Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients.
    Breast Cancer Res. 2024;26:162.
    >> Share

  208. CHEN H, Liu Y, Zhao J, Jia X, et al
    Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study.
    Breast Cancer Res. 2024;26:160.
    >> Share

  209. MERCOEUR B, Fervers B, Coudon T, Noh H, et al
    Exposure to air pollutants and breast cancer risk: mediating effects of metabolic health biomarkers in a nested case-control study within the E3N-Generations cohort.
    Breast Cancer Res. 2024;26:159.
    >> Share

  210. WADA K, Kuboyama K, Abe SK, Rahman MS, et al
    Body mass index and breast cancer risk in premenopausal and postmenopausal East Asian women: a pooled analysis of 13 cohort studies.
    Breast Cancer Res. 2024;26:158.
    >> Share

  211. XIONG L, Tang X, Jiang X, Chen H, et al
    Automatic segmentation-based multi-modal radiomics analysis of US and MRI for predicting disease-free survival of breast cancer: a multicenter study.
    Breast Cancer Res. 2024;26:157.
    >> Share

  212. LEE C, Yip H, Li JJX, Ng J, et al
    Clinical values of nuclear morphometric analysis in fibroepithelial lesions.
    Breast Cancer Res. 2024;26:156.
    >> Share

  213. KOOK Y, Lee YJ, Chu C, Jang JS, et al
    Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis.
    Breast Cancer Res. 2024;26:154.
    >> Share

  214. ZUO X, Zhao X, Zhang X, Li Q, et al
    PTPN20 promotes metastasis through activating NF-kappaB signaling in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:155.
    >> Share

  215. MANOUCHEHRI JM, Datta J, Marcho LM, Reardon JJ, et al
    The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:153.
    >> Share

  216. LEE YJ, Noh WC, Gwark S, Kim HA, et al
    Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.
    Breast Cancer Res. 2024;26:152.
    >> Share

  217. BUSUND M, Ursin G, Lund E, Chen SLF, et al
    Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study.
    Breast Cancer Res. 2024;26:151.
    >> Share

  218. CHRISTENSEN MH, Vinter CA, Olesen TB, Petersen MH, et al
    Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study.
    Breast Cancer Res. 2024;26:150.
    >> Share

    October 2024
  219. PUTHANMADHOM NARAYANAN S, Wedn AM, Shah OS, Chen J, et al
    Transcriptomic analysis identifies enrichment of cAMP/PKA/CREB signaling in invasive lobular breast cancer.
    Breast Cancer Res. 2024;26:149.
    >> Share

  220. ZHAO F, Polley E, McClellan J, Howard F, et al
    Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.
    Breast Cancer Res. 2024;26:148.
    >> Share

  221. JIN S, Zheng Y, Li D, Liu X, et al
    Effect of genistein supplementation on microenvironment regulation of breast tumors in obese mice.
    Breast Cancer Res. 2024;26:147.
    >> Share

  222. WU W, Zhu J, Nihira NT, Togashi Y, et al
    Ribosomal S6 kinase (RSK) plays a critical role in DNA damage response via the phosphorylation of histone lysine demethylase KDM4B.
    Breast Cancer Res. 2024;26:146.
    >> Share

  223. DWYER S, Ruth J, Seidel HE, Raz AA, et al
    Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy.
    Breast Cancer Res. 2024;26:143.
    >> Share

  224. CHEN J, Kehm R, Yang W, Terry MB, et al
    Increasing rates of early-onset Luminal A breast cancers correlate with binge drinking patterns.
    Breast Cancer Res. 2024;26:145.
    >> Share

  225. PILEHVARI A, Kimmick G, You W, Bonilla G, et al
    Disparities in receipt of 1-(st) line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting.
    Breast Cancer Res. 2024;26:144.
    >> Share

  226. LINDHOLM A, Abrahamsen ML, Buch-Larsen K, Marina D, et al
    Pro-inflammatory cytokines increase temporarily after adjuvant treatment for breast cancer in postmenopausal women: a longitudinal study.
    Breast Cancer Res. 2024;26:142.
    >> Share

  227. WU HC, Lai Y, Liao Y, Deyssenroth M, et al
    Plasma metabolomics profiles and breast cancer risk.
    Breast Cancer Res. 2024;26:141.
    >> Share

  228. NADER-MARTA G, Singer C, Hlauschek D, DeMichele A, et al
    Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
    Breast Cancer Res. 2024;26:140.
    >> Share

    September 2024
  229. O'DRISCOLL J, Burton A, Maskarinec G, Perez-Gomez B, et al
    Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study.
    Breast Cancer Res. 2024;26:139.
    >> Share

  230. SINN BV, Sychra K, Untch M, Karn T, et al
    On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res. 2024;26:138.
    >> Share

  231. JIANG B, Bao L, He S, Chen X, et al
    Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.
    Breast Cancer Res. 2024;26:137.
    >> Share

  232. BORAKA O, Sartor H, Sturesdotter L, Hall P, et al
    WHO-recommended levels of physical activity in relation to mammographic breast density, mammographic tumor appearance, and mode of detection of breast cancer.
    Breast Cancer Res. 2024;26:136.
    >> Share

  233. ZHANG N, Wang Q, Lu Y, Wang F, et al
    The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5.
    Breast Cancer Res. 2024;26:135.
    >> Share

  234. OZANNE EM, Maves K, Tramontano AC, Lynch T, et al
    Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25).
    Breast Cancer Res. 2024;26:134.
    >> Share

  235. TARANTO P, de Brito Sales D, Maluf FC, Guendelmann RAK, et al
    Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy.
    Breast Cancer Res. 2024;26:133.
    >> Share

  236. OMAR M, Harrell JC, Tamimi R, Marchionni L, et al
    A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.
    Breast Cancer Res. 2024;26:132.
    >> Share

  237. LIEN HC, Yu HC, Yu WH, Lin SF, et al
    Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinoma.
    Breast Cancer Res. 2024;26:130.
    >> Share

  238. PHUNG AT, Shah JR, Dong T, Reid T, et al
    CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.
    Breast Cancer Res. 2024;26:131.
    >> Share

  239. ZHANG Y, Zhong F, Liu L
    Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer.
    Breast Cancer Res. 2024;26:129.
    >> Share

  240. XUE X, Guo L, Guo C, Xu L, et al
    Challenges and improvements in HER2 scoring and histologic evaluation: insights from a national proficiency testing scheme for breast cancer diagnosis in China.
    Breast Cancer Res. 2024;26:128.
    >> Share

  241. STRAND SH, Houlahan KE, Branch V, Lynch T, et al
    Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome.
    Breast Cancer Res. 2024;26:127.
    >> Share

    August 2024
  242. INGEBRIKTSEN LM, Humlevik ROC, Svanoe AA, Saele AKM, et al
    Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features.
    Breast Cancer Res. 2024;26:126.
    >> Share

  243. VAN BOCKSTAL MR, Wesseling J, Lips EH, Smidt M, et al
    Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
    Breast Cancer Res. 2024;26:125.
    >> Share

  244. VALIERIS R, Martins L, Defelicibus A, Bueno AP, et al
    Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides.
    Breast Cancer Res. 2024;26:124.
    >> Share

  245. SHARMA A, Lovgren SK, Eriksson KL, Wang Y, et al
    Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images.
    Breast Cancer Res. 2024;26:123.
    >> Share

  246. MORAGAS N, Fernandez-Nogueira P, Recalde-Percaz L, Inman JL, et al
    The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.
    Breast Cancer Res. 2024;26:122.
    >> Share

  247. ZHAO Y, Song Y, Li X, Guo A, et al
    Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.
    Breast Cancer Res. 2024;26:121.
    >> Share

    July 2024
  248. LEE J, Park S, Bae SJ, Ji J, et al
    Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy.
    Breast Cancer Res. 2024;26:120.
    >> Share

  249. HAO J, Jin R, Yi Y, Jiang X, et al
    Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer.
    Breast Cancer Res. 2024;26:119.
    >> Share

  250. KADAMKULAM SYRIAC A, Nandu NS, Clark A, Tavallai M, et al
    Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes.
    Breast Cancer Res. 2024;26:118.
    >> Share

  251. HUANG Y, Chen C, Liu Y, Tan B, et al
    Downregulation of tRF-Cys-GCA-029 by hyperglycemia promotes tumorigenesis and glycolysis of diabetic breast cancer through upregulating PRKCG translation.
    Breast Cancer Res. 2024;26:117.
    >> Share

  252. MBURU W, Guo C, Tian Y, Koka H, et al
    Associations between quantitative measures of mammographic density and terminal ductal lobular unit involution in Chinese breast cancer patients.
    Breast Cancer Res. 2024;26:116.
    >> Share

  253. KADER T, Provenzano E, Jayawardana MW, Hendry S, et al
    Stromal lymphocytes are associated with upgrade of B3 breast lesions.
    Breast Cancer Res. 2024;26:115.
    >> Share

  254. GAO H, Wei L, Indulkar S, Nguyen TTL, et al
    Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.
    Breast Cancer Res. 2024;26:111.
    >> Share

  255. YANG X, Liu Q, Guo Z, Yang X, et al
    Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res. 2024;26:112.
    >> Share

  256. SUBRAMANYAN LV, Rasheed SAK, Wang L, Ghosh S, et al
    GNA13 suppresses proliferation of ER+ breast cancer cells via ERalpha dependent upregulation of the MYC oncogene.
    Breast Cancer Res. 2024;26:113.
    >> Share

  257. XIAO D, Zhang M, Qu Y, Su X, et al
    Functions of methyltransferase-like 3 in breast cancer: pathogenesis, drug resistance, and therapeutic target.
    Breast Cancer Res. 2024;26:110.
    >> Share

  258. HENG YJ, Baker GM, Fein-Zachary VJ, Guzman-Arocho YD, et al
    Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.
    Breast Cancer Res. 2024;26:109.
    >> Share

  259. WANG C, Nagayach A, Patel H, Dao L, et al
    Utilizing human cerebral organoids to model breast cancer brain metastasis in culture.
    Breast Cancer Res. 2024;26:108.
    >> Share

    June 2024
  260. SINEVICI N, Edmonds CE, Dontchos BN, Wang G, et al
    A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.
    Breast Cancer Res. 2024;26:107.
    >> Share

  261. FIFIELD BA, Vusich J, Haberfellner E, Andrechek ER, et al
    Atypical cell cycle regulation promotes mammary stem cell expansion during mammary development and tumourigenesis.
    Breast Cancer Res. 2024;26:106.
    >> Share

  262. WANG D, Yang S, Lyu M, Xu L, et al
    Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway.
    Breast Cancer Res. 2024;26:105.
    >> Share

  263. LU Y, Houson HA, Gallegos CA, Mascioni A, et al
    Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
    Breast Cancer Res. 2024;26:104.
    >> Share

  264. FANG Y, Wang Y, Ma H, Guo Y, et al
    TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription.
    Breast Cancer Res. 2024;26:103.
    >> Share

  265. HARRIS AR, Wang T, Heng YJ, Baker GM, et al
    Association of early menarche with breast tumor molecular features and recurrence.
    Breast Cancer Res. 2024;26:102.
    >> Share

  266. BHIMANI J, O'Connell K, Ergas IJ, Foley M, et al
    Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019.
    Breast Cancer Res. 2024;26:101.
    >> Share

  267. ZHANG Y, Chen F, Balic M, Creighton CJ, et al
    An essential gene signature of breast cancer metastasis reveals targetable pathways.
    Breast Cancer Res. 2024;26:98.
    >> Share

  268. LIEN HC, Lo C, Lee YH, Lin PH, et al
    In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
    Breast Cancer Res. 2024;26:100.
    >> Share

  269. DU J, Liu X, Sun J, Wu Q, et al
    Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:99.
    >> Share

  270. LEON-FERRE RA, Whitaker KR, Suman VJ, Hoskin T, et al
    Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
    Breast Cancer Res. 2024;26:97.
    >> Share

  271. COLEMAN MF, Cotul EK, Pfeil AJ, Devericks EN, et al
    Hypoxia-mediated repression of pyruvate carboxylase drives immunosuppression.
    Breast Cancer Res. 2024;26:96.
    >> Share

  272. LAINE M, Greene ME, Kurleto JD, Bozek G, et al
    Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.
    Breast Cancer Res. 2024;26:95.
    >> Share

  273. ZHANG X, An K, Ge X, Sun Y, et al
    NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m(5)C methylation.
    Breast Cancer Res. 2024;26:94.
    >> Share

  274. DUIVON M, Lequesne J, Di Meglio A, Pradon C, et al
    Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
    Breast Cancer Res. 2024;26:93.
    >> Share

  275. JIN X, Yang S, Lu X, Chen X, et al
    Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
    Breast Cancer Res. 2024;26:92.
    >> Share

  276. FARALDO MM, Romagnoli M, Wallon L, Dubus P, et al
    Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
    Breast Cancer Res. 2024;26:91.
    >> Share

  277. MORLA-BARCELO PM, Laguna-Macarrilla D, Cordoba O, Matheu G, et al
    Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.
    Breast Cancer Res. 2024;26:89.
    >> Share

  278. BOISSIN C, Wang Y, Sharma A, Weitz P, et al
    Deep learning-based risk stratification of preoperative breast biopsies using digital whole slide images.
    Breast Cancer Res. 2024;26:90.
    >> Share

    May 2024
  279. JOHN EM, Koo J, Phipps AI, Longacre TA, et al
    Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    Breast Cancer Res. 2024;26:88.
    >> Share

  280. GLOTZBACH A, Rohlf K, Gonscharow A, Luke S, et al
    EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis.
    Breast Cancer Res. 2024;26:87.
    >> Share

  281. RAGHURAM N, Temel EI, Kawamata T, Kozma KJ, et al
    Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
    Breast Cancer Res. 2024;26:86.
    >> Share

  282. JONES LI, Marshall A, Geach R, Elangovan P, et al
    Optimising the diagnostic accuracy of First post-contrAst SubtracTed breast MRI (FAST MRI) through interpretation-training: a multicentre e-learning study, mapping the learning curve of NHS Breast Screening Programme (NHSBSP) mammogram readers using a
    Breast Cancer Res. 2024;26:85.
    >> Share

  283. KUKLINSKI D, Blum M, Subelack J, Geissler A, et al
    Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survival.
    Breast Cancer Res. 2024;26:84.
    >> Share

  284. JACOBS SA, Wang Y, Abraham J, Feng H, et al
    Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:83.
    >> Share

  285. LIU C, Sun M, Arefan D, Zuley M, et al
    Deep learning of mammogram images to reduce unnecessary breast biopsies: a preliminary study.
    Breast Cancer Res. 2024;26:82.
    >> Share

  286. VAN CAUWENBERGE J, Van Baelen K, Maetens M, Geukens T, et al
    Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.
    Breast Cancer Res. 2024;26:81.
    >> Share

  287. MAO H, Jin M, Xie L, Mao N, et al
    Infrared laser moxibustion for cancer-related fatigue in breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2024;26:80.
    >> Share

  288. NELSON A, McMullen N, Gebremeskel S, De Antueno R, et al
    Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Breast Cancer Res. 2024;26:78.
    >> Share

  289. MARIAPUN S, Ho WK, Eriksson M, Mohd Taib NA, et al
    Association of area- and volumetric-mammographic density and breast cancer risk in women of Asian descent: a case control study.
    Breast Cancer Res. 2024;26:79.
    >> Share

  290. ZHANG X, Teng X, Zhang J, Lai Q, et al
    Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
    Breast Cancer Res. 2024;26:77.
    >> Share

  291. RAJ-KUMAR PK, Lin X, Liu T, Sturtz LA, et al
    Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.
    Breast Cancer Res. 2024;26:76.
    >> Share

  292. OMILIAN AR, Cannioto R, Mendicino L, Stein L, et al
    CD163(+) macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-Up Study.
    Breast Cancer Res. 2024;26:75.
    >> Share

    April 2024
  293. SMITH RE, Sprague BL, Henderson LM, Kerlikowske K, et al
    Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.
    Breast Cancer Res. 2024;26:73.
    >> Share

  294. CHAUDHARY P, Yadav K, Lee HJ, Kang KW, et al
    siRNA treatment targeting integrin alpha11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
    Breast Cancer Res. 2024;26:72.
    >> Share

  295. HE L, Qin Y, Hu Q, Liu Z, et al
    Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging.
    Breast Cancer Res. 2024;26:71.
    >> Share

  296. LIAO R, Chen X, Cao Q, Bai L, et al
    AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.
    Breast Cancer Res. 2024;26:70.
    >> Share

  297. JACOBS SA, Wang Y, Abraham J, Feng H, et al
    NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:69.
    >> Share

  298. PAN JW, Ragu M, Chan WQ, Hasan SN, et al
    Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
    Breast Cancer Res. 2024;26:67.
    >> Share

  299. KWON MR, Chang Y, Ham SY, Cho Y, et al
    Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection.
    Breast Cancer Res. 2024;26:68.
    >> Share

  300. BAE SJ, Chun JW, Lee SB, Ryu JM, et al
    Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study.
    Breast Cancer Res. 2024;26:66.
    >> Share


  301. Meeting Abstracts from the British Society of Breast Radiology annual scientific meeting 2023.
    Breast Cancer Res. 2024;26.
    >> Share

  302. ZHANG N, Huang Y, Wang G, Xiang Y, et al
    Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer.
    Breast Cancer Res. 2024;26:64.
    >> Share

  303. BAE SJ, Kook Y, Jang JS, Baek SH, et al
    Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
    Breast Cancer Res. 2024;26:65.
    >> Share

  304. SALEMBIER R, De Haes C, Bellemans J, Demeyere K, et al
    Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
    Breast Cancer Res. 2024;26:63.
    >> Share

  305. ZHANG W, Song X, Jin Z, Zhang Y, et al
    U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
    Breast Cancer Res. 2024;26:60.
    >> Share

  306. KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
    Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival.
    Breast Cancer Res. 2024;26:61.
    >> Share

  307. WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
    Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Breast Cancer Res. 2024;26:59.
    >> Share

  308. BASHARI MH, Fan F, Vallet S, Sattler M, et al
    Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
    Breast Cancer Res. 2024;26:58.
    >> Share

    March 2024
  309. OLIPHANT MUJ, Akshinthala D, Muthuswamy SK
    Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.
    Breast Cancer Res. 2024;26:56.
    >> Share

  310. CHI F, Griffiths JI, Nath A, Bild AH, et al
    Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Breast Cancer Res. 2024;26:54.
    >> Share

  311. SAFAEI S, Fadaee M, Farzam OR, Yari A, et al
    Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.
    Breast Cancer Res. 2024;26:57.
    >> Share

  312. WALLACE G, Kundalia R, Vallebuona E, Cao B, et al
    Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
    Breast Cancer Res. 2024;26:55.
    >> Share

  313. MULLOOLY M, Fan S, Pfeiffer RM, Bowles EA, et al
    Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease.
    Breast Cancer Res. 2024;26:52.
    >> Share

  314. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:53.
    >> Share

  315. HAMILTON AM, Walens A, Van Alsten SC, Olsson LT, et al
    BIRC5 expression by race, age and clinical factors in breast cancer patients.
    Breast Cancer Res. 2024;26:50.
    >> Share

  316. MCCLELLAN JC, Li JL, Gao G, Huo D, et al
    Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status.
    Breast Cancer Res. 2024;26:51.
    >> Share

  317. LEE J, Lee G, Park HS, Jeong BK, et al
    Factors associated with engraftment success of patient-derived xenografts of breast cancer.
    Breast Cancer Res. 2024;26:49.
    >> Share

  318. HU R, Cao Y, Wang Y, Zhao T, et al
    TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via beta1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Breast Cancer Res. 2024;26:48.
    >> Share

  319. GONZALEZ-FERNANDEZ L, Romero-Morales C, Martinez-Pascual B, Rio-Gonzalez A, et al
    Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study.
    Breast Cancer Res. 2024;26:47.
    >> Share

  320. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
    Breast Cancer Res. 2024;26:46.
    >> Share

  321. PEREIRA A, Garmendia ML, Leiva V, Corvalan C, et al
    Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study.
    Breast Cancer Res. 2024;26:45.
    >> Share

  322. JACOBS LM, Helder LS, Albers KI, Kranendonk J, et al
    The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study.
    Breast Cancer Res. 2024;26:42.
    >> Share

  323. CONNER SJ, Guarin JR, Le TT, Fatherree JP, et al
    Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.
    Breast Cancer Res. 2024;26:43.
    >> Share

  324. BAEZ-NAVARRO X, van den Ende NS, Nguyen AH, Sinke R, et al
    HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Breast Cancer Res. 2024;26:41.
    >> Share

  325. LI J, Liang Y, Zhou S, Chen J, et al
    UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
    Breast Cancer Res. 2024;26:44.
    >> Share

  326. ZHAO L, Xing Y, Liu C, Ma S, et al
    Detection of HER2 expression using (99m)Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
    Breast Cancer Res. 2024;26:40.
    >> Share

  327. CASTRESANA-AGUIRRE M, Johansson A, Matikas A, Foukakis T, et al
    Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Breast Cancer Res. 2024;26:38.
    >> Share

  328. HAN Y, Otegbeye EE, Stoll C, Hardi A, et al
    How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis.
    Breast Cancer Res. 2024;26:39.
    >> Share

  329. JIANG X, Wang Y, Guo L, Wang Y, et al
    The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
    Breast Cancer Res. 2024;26:37.
    >> Share

  330. RODON J, Demanse D, Rugo HS, Burris HA, et al
    A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
    Breast Cancer Res. 2024;26:36.
    >> Share

  331. SMOOTS SG, Schreiber AR, Jackson MM, Bagby SM, et al
    Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Breast Cancer Res. 2024;26:35.
    >> Share

    February 2024
  332. SONG T, Zhang H, Zhao Q, Hu Z, et al
    Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
    Breast Cancer Res. 2024;26:33.
    >> Share

  333. EDWARDS CM, Kane JF, Smith JA, Grant DM, et al
    PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
    Breast Cancer Res. 2024;26:34.
    >> Share

  334. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
    Breast Cancer Res. 2024;26:32.
    >> Share

  335. JUNG M, Song SG, Cho SI, Shin S, et al
    Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
    Breast Cancer Res. 2024;26:31.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016